Today's Rundown - Merlo: CVS seeing massive increases in telehealth use, home prescription delivery due to COVID-19
- AdvaMed, defense contractors team up to supply ventilator parts
- Gilead, working on its own remdesivir ramp-up, scouts licensing partners for global production
- Health system experts: Don't expect return to pre-COVID-19 business before vaccine, herd immunity
- CSL Behring joins pandemic R&D fight with antibody work
- Healthcare roundup: Michigan Medicine furloughs 1,400; Intermountain begins antibody testing
- Lilly ramps up to beat the virus with neutralizing antibodies as scientists raise worries
- U.S., U.K. security agencies warn state-based hackers targeting healthcare, medical research
- Novartis taps real-life Cosentyx patients to thank healthcare workers, pledge patient support
- Portraits in Healthcare: Baylor St. Luke's Medical Center doctor on COVID: 'It’s been a very humbling experience'
- Physicians are looking to pharma for COVID-19 comms. Where are they?
- Sidelined by COVID-19 pandemic, Team Novo Nordisk cyclists crank and jam on social media instead
Featured Story | | | Wednesday, May 6, 2020 CVS Health earned $2 billion in profit for the first quarter, beating Wall Street expectations. |
|
|---|
|
Top Stories Wednesday, May 6, 2020 AdvaMed launched an online platform to put ventilator manufacturers in touch with potential suppliers of much-needed components, as more companies pivot toward the coronavirus pandemic, including aerospace and defense companies. Wednesday, May 6, 2020 Gilead Sciences can only produce so much of its newly authorized COVID-19 med remdesivir, so it’s scouting other companies to bolster global supply. The Big Biotech is in licensing talks with major players, including generics makers in India and Pakistan, to produce enough of the antiviral for countries around the world. Wednesday, May 6, 2020 While hospitals around the country are carefully moving forward opening up business such as offering elective surgeries again, don't expect them to get back to pre-COVID-19 volumes anytime soon, experts said during a recent FierceHealthcare Coronavirus Virtual Series. Wednesday, May 6, 2020 Australia’s largest biotech company CSL says it is working on a plasma-based therapy for patients with more severe forms of COVID-19. Wednesday, May 6, 2020 FierceHealthcare's ongoing coverage of how the coronavirus is impacting the healthcare industry. Wednesday, May 6, 2020 Eli Lilly has teamed with China’s Junshi Biosciences in the U.S., marking the company's second COVID-19 pact to develop neutralizing antibodies against the virus. It promises to be a faster approach than designing a new small-molecule drug would be, but getting from idea to an effective product may not be so simple. Wednesday, May 6, 2020 Cybersecurity authorities in the U.S. and U.K. are warning that nation-state hackers are after intellectual property and medical research related to COVID-19 treatments. Wednesday, May 6, 2020 Novartis is using familiar faces—real patients from its Cosentyx TV commercials—to thank healthcare workers and promise support for patients. It’s a shift away from product-centered TV ads as Novartis adjusts its Cosentyx DTC effort during the COVID-19 crisis to highlight resources for patients, the drugmaker said. Wednesday, May 6, 2020 Michele Loor, M.D., typically splits her time between surgery and critical care at Baylor St. Luke's Medical Center. But in recent weeks, her shifts have been solely in the ICU as severe cases threatened to overwhelm the hospital. She shares some of her thoughts now that admissions seem to have stabilized. Wednesday, May 6, 2020 During the COVID-19 crisis, physicians want specific treatment protocols tailored to their patient populations. And almost half want specific COVID-19-related information from pharma companies, according to a new survey from pharma and healthcare agency AbelsonTaylor. But that info has been slow to arrive. Wednesday, May 6, 2020 What does a professional cycling team do when it can’t ride? For Team Novo Nordisk, switch gears to social media. The all-diabetes professional cycling team should be well into the 2020 season, but instead has taken to Twitter, Instagram, Facebook and LinkedIn with news, interviews, training tips, throwbacks to past races, contests (#GuessTheRider) and general encouragement. |
|
